Cimetidine in duodenal ulcer. Controlled trial.
As part of a double-blind controlled clinical trial of cimetidine (1.6 g daily) in patients with endoscopically proven duodenal ulcer, repeat endoscopy has been carried out in 24 patients after two and/or six weeks' treatment. At six weeks, 9 out of 11 patients on cimetidine and 3 out of 12 patients on placebo had healed (P less than 0.025). A separate open pilot trial in 23 patients has shown no difference in ulcer healing at six weeks between patients taking 0.8 and 1.6 g daily. A total of 32 different patients received cimetidine in the two trials, and ulcer healing was observed in 21 (66%) at six weeks. No patients showed evidence of bone-marrow toxicity. A small but significant rise in mean S.G.O.T., S.G.P.T., and serum-creatinine occurred in 13 patients on cimetidine 1.6 g daily, but not in 13 patients on 0.8 g daily.
D002927:Cimetidine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D010919:Placebos; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects
D006146:Guanidines; D010919:Placebos; D002927:Cimetidine